Michael Moroney

Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial

Deepak L. Bhatt, Lawrence A Leiter, M. Lafreniere-Roula, 2022, Circulation.

Impact of diabetes duration on left ventricular mass regression with empagliflozin

A. Yan, K. Connelly, C. Mazer, 2023, ESC heart failure.

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling

S. Verma, A. Yan, K. Connelly, 2023, ESC heart failure.